Ascent Pharmaceuticals announces that it will announce six latest preclinical developments at the 2021 American Association for Cancer Research Annual Meeting

The six research results of Ascent Pharmaceuticals were selected into the AACR poster and displayed as follows:

title:

• Abstract/Poster Number: 981
• Session Category: Experimental and Molecular Therapeutics
  
  

  Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

  BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

  • Abstract/Poster Number: 976
  • Session Category: Experimental and Molecular Therapeutics
    
    

    FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)

    FMS-like tyrosine kinase 3 (FLT3) inhibitor oribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

    • Abstract/Poster Number: 1096
    • Session Category: Experimental and Molecular Therapeutics
      
      

      Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

      Research on the therapeutic potential of inhibitor of apoptosis protein (IAP) APG-1387 combined with DR5 agonist CTB-006 monoclonal antibody (mAb) in preclinical models of solid tumors

      • Abstract/Poster Number: 1924
      • Breakout Category: Molecular and Cellular Biology / Genetics
        
        

        Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

        APG-1252 (pelcitoclax) inhibits BCL-xL to overcome neuroendocrine tumor (NEN) cell apoptosis

        • Abstract/Poster Number: 984
        • Session Category: Experimental and Molecular Therapeutics
          
          

          Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

          Focal adhesion kinase (FAK) inhibitor APG-2449 enhances the sensitivity of ovarian cancer to chemotherapy by down-regulating CD44

          • Abstract/Poster Number: 968
          • Session Category: Experimental and Molecular Therapeutics
            Experimental and Molecular Therapy
          • Session Title: Biological Therapeutic Agents
            Biotherapeutics